Panfor SR

Panfor SR (manufactured by Inventia Healthcare / Medley Pharmaceuticals) is a sustained-release formulation of metformin hydrochloride, an oral biguanide antihyperglycemic medication used in the management of type 2 diabetes mellitus. Panfor SR utilizes a matrix delivery system that gradually releases active metformin throughout the gastrointestinal tract over an extended duration. This sustained release minimizes peak plasma concentration spikes, providing smoother blood glucose control and significantly reducing the gastrointestinal adverse effects (such as diarrhea, nausea, and abdominal cramps) common with immediate-release metformin.

Like standard metformin, Panfor SR works without stimulating pancreatic insulin secretion, thereby carrying a minimal risk of hypoglycemia when used as monotherapy. Its core mechanisms include:

• Inhibition of Hepatic Gluconeogenesis: Decreasing excess glucose production in the liver.

• Enhanced Peripheral Insulin Sensitivity: Improving insulin-mediated glucose uptake and uptake efficiency in skeletal muscle and peripheral tissues.

• Reduced Intestinal Absorption: Slowing the absorption rate of glucose across the gastrointestinal tract.

Primary Medical Indications

Panfor SR is indicated for adult and pediatric patients (aged 10 years and older, depending on regional guidelines) for the management of metabolic and endocrine conditions:

• Type 2 Diabetes Mellitus: Used as first-line monotherapy or in combination with other oral antidiabetic agents (e.g., sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors) or insulin to lower blood glucose and HbA1c levels alongside diet and exercise.

• Intolerance to Immediate-Release Metformin: Ideal step-down/switch option for patients experiencing severe gastrointestinal side effects on standard immediate-release metformin.

• Polycystic Ovary Syndrome (PCOS): Off-label administration to manage insulin resistance, reduce hyperandrogenism, and regulate ovulatory cycles in women with PCOS.

• Prediabetes Management: Off-label or approved protocol use to delay or prevent progression to overt type 2 diabetes in high-risk individuals with impaired fasting glucose.

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Do Not Crush, Chew, or Split: Panfor SR relies on an intact sustained-release matrix. Crushing or chewing the tablet destroys this mechanism, releasing the entire dose immediately and increasing the risk of adverse GI reactions and dose dumping.

• Boxed Warning for Lactic Acidosis: Metformin accumulation can trigger lactic acidosis, a rare but life-threatening metabolic emergency. Risk factors include significant renal impairment (eGFR less than 30 mL/min/1.73 $\text{m}^2$), severe hepatic failure, acute cardiac failure, sepsis, and heavy alcohol intake.

• Iodinated Contrast Procedures: Temporarily discontinue Panfor SR before or at the time of intravascular iodinated contrast radiological procedures in patients with eGFR between 30 and 60 mL/min/1.73 $\text{m}^2$ or with hepatic risk factors.

• Vitamin $B_{12}$ Monitoring: Long-term metformin therapy can impair intestinal absorption of vitamin $B_{12}$, potentially causing megaloblastic anemia or peripheral neuropathy. Routine serum $B_{12}$ testing is recommended every 1 to 2 years.